The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Venous Thromboembolism Drug Market Research Report 2025

Global Venous Thromboembolism Drug Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1603697

No of Pages : 87

Ask Your Query

Synopsis

Venous Thromboembolism?includes both deep vein thrombosis (DVT) and pulmonary embolism (PE).

The global Venous Thromboembolism Drug market was valued at US$ 2254 million in 2023 and is anticipated to reach US$ 3272.5 million by 2030, witnessing a CAGR of 5.3% during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Venous Thromboembolism Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Venous Thromboembolism Drug.

Report Scope

The Venous Thromboembolism Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Venous Thromboembolism Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Venous Thromboembolism Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company

  • Bayer
  • BMS
  • Boehringer Ingelheim
  • Daiichi Sankyo
  • J&J
  • Sanofi
  • Altor Bioscience
  • Armetheon
  • Aspen Pharma
  • BioInvent
  • eXIthera Pharmaceuticals
  • Gamma Therapeutics

Segment by Type

  • Heparin
  • Apixaban
  • Dabigatran
  • Rivaroxaban
  • Edaxaban
  • Warfarin

Segment by Application

  • Hospital
  • Clinic

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Venous Thromboembolism Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Venous Thromboembolism Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Index

1 Venous Thromboembolism Drug Market Overview
1.1 Product Overview and Scope of Venous Thromboembolism Drug
1.2 Venous Thromboembolism Drug Segment by Type
1.2.1 Global Venous Thromboembolism Drug Market Value Comparison by Type (2024-2030)
1.2.2 Heparin
1.2.3 Apixaban
1.2.4 Dabigatran
1.2.5 Rivaroxaban
1.2.6 Edaxaban
1.2.7 Warfarin
1.3 Venous Thromboembolism Drug Segment by Application
1.3.1 Global Venous Thromboembolism Drug Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Venous Thromboembolism Drug Market Size Estimates and Forecasts
1.4.1 Global Venous Thromboembolism Drug Revenue 2019-2030
1.4.2 Global Venous Thromboembolism Drug Sales 2019-2030
1.4.3 Global Venous Thromboembolism Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Venous Thromboembolism Drug Market Competition by Manufacturers
2.1 Global Venous Thromboembolism Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Venous Thromboembolism Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Venous Thromboembolism Drug Average Price by Manufacturers (2019-2024)
2.4 Global Venous Thromboembolism Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Venous Thromboembolism Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Venous Thromboembolism Drug, Product Type & Application
2.7 Venous Thromboembolism Drug Market Competitive Situation and Trends
2.7.1 Venous Thromboembolism Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Venous Thromboembolism Drug Players Market Share by Revenue
2.7.3 Global Venous Thromboembolism Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Venous Thromboembolism Drug Retrospective Market Scenario by Region
3.1 Global Venous Thromboembolism Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Venous Thromboembolism Drug Global Venous Thromboembolism Drug Sales by Region: 2019-2030
3.2.1 Global Venous Thromboembolism Drug Sales by Region: 2019-2024
3.2.2 Global Venous Thromboembolism Drug Sales by Region: 2025-2030
3.3 Global Venous Thromboembolism Drug Global Venous Thromboembolism Drug Revenue by Region: 2019-2030
3.3.1 Global Venous Thromboembolism Drug Revenue by Region: 2019-2024
3.3.2 Global Venous Thromboembolism Drug Revenue by Region: 2025-2030
3.4 North America Venous Thromboembolism Drug Market Facts & Figures by Country
3.4.1 North America Venous Thromboembolism Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Venous Thromboembolism Drug Sales by Country (2019-2030)
3.4.3 North America Venous Thromboembolism Drug Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Venous Thromboembolism Drug Market Facts & Figures by Country
3.5.1 Europe Venous Thromboembolism Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Venous Thromboembolism Drug Sales by Country (2019-2030)
3.5.3 Europe Venous Thromboembolism Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Venous Thromboembolism Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Venous Thromboembolism Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Venous Thromboembolism Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Venous Thromboembolism Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Venous Thromboembolism Drug Market Facts & Figures by Country
3.7.1 Latin America Venous Thromboembolism Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Venous Thromboembolism Drug Sales by Country (2019-2030)
3.7.3 Latin America Venous Thromboembolism Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Venous Thromboembolism Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Venous Thromboembolism Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Venous Thromboembolism Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Venous Thromboembolism Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Venous Thromboembolism Drug Sales by Type (2019-2030)
4.1.1 Global Venous Thromboembolism Drug Sales by Type (2019-2024)
4.1.2 Global Venous Thromboembolism Drug Sales by Type (2025-2030)
4.1.3 Global Venous Thromboembolism Drug Sales Market Share by Type (2019-2030)
4.2 Global Venous Thromboembolism Drug Revenue by Type (2019-2030)
4.2.1 Global Venous Thromboembolism Drug Revenue by Type (2019-2024)
4.2.2 Global Venous Thromboembolism Drug Revenue by Type (2025-2030)
4.2.3 Global Venous Thromboembolism Drug Revenue Market Share by Type (2019-2030)
4.3 Global Venous Thromboembolism Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Venous Thromboembolism Drug Sales by Application (2019-2030)
5.1.1 Global Venous Thromboembolism Drug Sales by Application (2019-2024)
5.1.2 Global Venous Thromboembolism Drug Sales by Application (2025-2030)
5.1.3 Global Venous Thromboembolism Drug Sales Market Share by Application (2019-2030)
5.2 Global Venous Thromboembolism Drug Revenue by Application (2019-2030)
5.2.1 Global Venous Thromboembolism Drug Revenue by Application (2019-2024)
5.2.2 Global Venous Thromboembolism Drug Revenue by Application (2025-2030)
5.2.3 Global Venous Thromboembolism Drug Revenue Market Share by Application (2019-2030)
5.3 Global Venous Thromboembolism Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Corporation Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bayer Venous Thromboembolism Drug Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 BMS
6.2.1 BMS Corporation Information
6.2.2 BMS Description and Business Overview
6.2.3 BMS Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 BMS Venous Thromboembolism Drug Product Portfolio
6.2.5 BMS Recent Developments/Updates
6.3 Boehringer Ingelheim
6.3.1 Boehringer Ingelheim Corporation Information
6.3.2 Boehringer Ingelheim Description and Business Overview
6.3.3 Boehringer Ingelheim Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Boehringer Ingelheim Venous Thromboembolism Drug Product Portfolio
6.3.5 Boehringer Ingelheim Recent Developments/Updates
6.4 Daiichi Sankyo
6.4.1 Daiichi Sankyo Corporation Information
6.4.2 Daiichi Sankyo Description and Business Overview
6.4.3 Daiichi Sankyo Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Daiichi Sankyo Venous Thromboembolism Drug Product Portfolio
6.4.5 Daiichi Sankyo Recent Developments/Updates
6.5 J&J
6.5.1 J&J Corporation Information
6.5.2 J&J Description and Business Overview
6.5.3 J&J Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 J&J Venous Thromboembolism Drug Product Portfolio
6.5.5 J&J Recent Developments/Updates
6.6 Sanofi
6.6.1 Sanofi Corporation Information
6.6.2 Sanofi Description and Business Overview
6.6.3 Sanofi Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Sanofi Venous Thromboembolism Drug Product Portfolio
6.6.5 Sanofi Recent Developments/Updates
6.7 Altor Bioscience
6.6.1 Altor Bioscience Corporation Information
6.6.2 Altor Bioscience Description and Business Overview
6.6.3 Altor Bioscience Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Altor Bioscience Venous Thromboembolism Drug Product Portfolio
6.7.5 Altor Bioscience Recent Developments/Updates
6.8 Armetheon
6.8.1 Armetheon Corporation Information
6.8.2 Armetheon Description and Business Overview
6.8.3 Armetheon Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Armetheon Venous Thromboembolism Drug Product Portfolio
6.8.5 Armetheon Recent Developments/Updates
6.9 Aspen Pharma
6.9.1 Aspen Pharma Corporation Information
6.9.2 Aspen Pharma Description and Business Overview
6.9.3 Aspen Pharma Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Aspen Pharma Venous Thromboembolism Drug Product Portfolio
6.9.5 Aspen Pharma Recent Developments/Updates
6.10 BioInvent
6.10.1 BioInvent Corporation Information
6.10.2 BioInvent Description and Business Overview
6.10.3 BioInvent Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2019-2024)
6.10.4 BioInvent Venous Thromboembolism Drug Product Portfolio
6.10.5 BioInvent Recent Developments/Updates
6.11 eXIthera Pharmaceuticals
6.11.1 eXIthera Pharmaceuticals Corporation Information
6.11.2 eXIthera Pharmaceuticals Venous Thromboembolism Drug Description and Business Overview
6.11.3 eXIthera Pharmaceuticals Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2019-2024)
6.11.4 eXIthera Pharmaceuticals Venous Thromboembolism Drug Product Portfolio
6.11.5 eXIthera Pharmaceuticals Recent Developments/Updates
6.12 Gamma Therapeutics
6.12.1 Gamma Therapeutics Corporation Information
6.12.2 Gamma Therapeutics Venous Thromboembolism Drug Description and Business Overview
6.12.3 Gamma Therapeutics Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Gamma Therapeutics Venous Thromboembolism Drug Product Portfolio
6.12.5 Gamma Therapeutics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Venous Thromboembolism Drug Industry Chain Analysis
7.2 Venous Thromboembolism Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Venous Thromboembolism Drug Production Mode & Process
7.4 Venous Thromboembolism Drug Sales and Marketing
7.4.1 Venous Thromboembolism Drug Sales Channels
7.4.2 Venous Thromboembolism Drug Distributors
7.5 Venous Thromboembolism Drug Customers
8 Venous Thromboembolism Drug Market Dynamics
8.1 Venous Thromboembolism Drug Industry Trends
8.2 Venous Thromboembolism Drug Market Drivers
8.3 Venous Thromboembolism Drug Market Challenges
8.4 Venous Thromboembolism Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock